Iovance Biotherapeutics Announces Clinical Trial Updates with Collaborators MD Anderson and Moffitt Cancer Center
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: GlobeNewswire
- First Patient Dosed with LN-145 in Phase 2 Trial with MD Anderson for Treatment of Sarcomas and Ovarian Cancer - - Preliminary Data from Moffitt NSCLC Study to be Presented at the Upcoming 19th World Conference on Lung Cancer in September 2018 - SAN CARLOS, Calif., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced updates from its clinical collaborations with The University of Texas MD Anderson Cancer Center (MD Anderson) and Moffitt Cancer Center (Moffitt). Under the MD Anderson collaboration, the company announced that the first patient was dosed with LN-145 in the Phase 2, multi-arm clinical trial (NCT03449108). The company also announced that preliminary data from an investigator-sponsored Non-Small Cell Lung Cancer (NSCLC) study with Moffitt will be presented at the upcoming IASLC 19th World Conference on Lun
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- 3 Millionaire-Maker Biotech Stocks [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual MeetingGlobeNewswire
- These Biotech Stocks Could Soar 120% and 295%, According to Wall Street [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Is Iovance Biotherapeutics Stock a Buy Now? [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/28/24 - Miss
IOVA
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- IOVA's page on the SEC website